23andme Holding Co logo

23andme Holding Co Share Price (NASDAQ: ME)

▲

-0.77

(-100%)

Last updated on

Bell Icon

The stock has been delisted from the stock exchange on 27 Mar 2025

Check the interactive 23andme Holding Co Stock chart to analyse performance

23andme Holding Co Key Stats

Check 23andme Holding Co key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$0.77
Open
$0.748
Market Capitalization
$15.2M
Today's Volume
$29.3M
Revenue TTM
$208.8M
EBITDA
$-219.7M
Earnings Per Share (EPS)
$-17.39
Profit Margin
-186.98%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-193.76%

Global Institutional Holdings in 23andme Holding Co

  • Name

    Holdings %

  • Vanguard Group Inc

    2.90%

  • Shay Capital LLC

    2.62%

  • Sapphire Ventures (GPE) I, L.L.C.

    0.99%

  • Jane Street Group LLC

    0.96%

  • BlackRock Inc

    0.89%

  • Millennium Management LLC

    0.83%

Analyst Recommendation on 23andme Holding Co Stock

Rating
Trend

Buy

    80%Buy

    20%Hold

    0%Sell

Based on 10 Wall street analysts offering stock ratings for 23andme Holding Co(by analysts ranked 0 to 5 stars)

About 23andme Holding Co

23andMe Holding Co. operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally. The company operates in two segments, Consumer and Research Services, and Therapeutics. The Consumer and Research Services segment provides personal genome service (PGS) that consists of a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the development of novel therapies; and research and development of programs in various therapeutic areas, such as oncology, immunological and inflammatory diseases, and other disease areas, as well as engages in the out-licensing of intellectual property associated with identified drug targets and expenses related to the discovery and development of therapeutic product candidates. This segment also comprises a therapeutics product portfolio, including 23ME-00610 (P006), a humanized monoclonal antibody that interfere with the ability of CD200R1 to interact with CD200 in cancer cells; GSK6097608, an immuno-oncology program for targeting CD96; and 23ME-01473 is an immuno-oncology antibody program that targets the ULBP6 proteins in the NKG2D pathway. The company has collaboration with Mirador Therapeutics to advance mirador's precision medicines for immunology and inflammation. 23andMe Holding Co. was founded in 2006 and is headquartered in South San Francisco, California. On March 23, 2025, 23andMe Holding Co., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of Missouri.
Organization
23andme Holding Co
Employees
560
CEO
Mr. Guy Chayoun
Industry
Miscellaneous

Key Management of 23andme Holding Co

NameTitle
Mr. Guy Chayoun
VP, Interim General Counsel & Corporate Secretary
Ms. Tracy Keim
Chief Marketing Officer
Ms. Savita Pillai
Vice President of People
Mr. Kent Hillyer
Vice President of Consumer Operations
Mr. Daniel Chu
Chief Product Officer
Mr. Frank Russo
Chief Security Officer

Important FAQs about investing in ME Stock from India :

What is 23andme Holding Co share price today?

23andme Holding Co share price today is as on at the close of the market. 23andme Holding Co share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for 23andme Holding Co share?

23andme Holding Co share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. 23andme Holding Co stock price today i.e. is closed at , lower by 100% versus the 52 week high.

How to invest in 23andme Holding Co Stock (ME) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for 23andme Holding Co on INDmoney app. Click on Buy button. You can invest as low as $1.5 in 23andme Holding Co Shares .

What is the minimum amount required to buy 23andme Holding Co Stock (ME) from India?

Indian investors can start investing in 23andme Holding Co (ME) shares with as little as ₹88.167 or $1 (as of August 29, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹881.67 in 23andme Holding Co stock (as per the Rupee-Dollar exchange rate as on August 29, 2025). Learn more about fractional shares .

What are the returns that 23andme Holding Co has given to Indian investors in the last 5 years?

23andme Holding Co stock has given 0.0% share price returns and 20.35% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?